Sandoz Is Stalled On Swiss Pemetrexed
Prior-Art Arguments Against Alimta Vitamin Patent Fall Short
Sandoz’ unsuccessful attempts to show a lack of inventive step in a Swiss vitamin regimen patent leave Lilly’s Alimta pemetrexed brand protected until 2021.
